Discovered by BIOTEC research team together with the Medicines for Malaria Venture (MMV), the patented P218 compound was designed based-on 3-dimensional structures of malaria protein target, dihydrofolate reductase, in order to circumvent mutations that had led to resistance to pyrimethamine, […]
Recent Posts
- FAO Director-General Visits BIOTEC to Explore Biotechnology Innovations for Sustainable Agrifood Systems
08/30/2026 - BIOTEC Executive Delegation Strengthens Strategic Research Partnership with CSIRO in Australia
08/20/2026 - Cambridge and BIOTEC Researchers Join Thailand-International Networks to Advance One Health Action against Streptococcus suis: From Research to Prevention
07/17/2026